Literature DB >> 19765814

Intermittent preventive treatment of malaria in infancy.

Rose McGready1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19765814     DOI: 10.1016/S0140-6736(09)61629-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Intermittent preventive treatment for malaria in sub-saharan African: a halfway technology or a critical intervention?

Authors:  Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

2.  Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination.

Authors:  Frans Herwig Jansen
Journal:  Malar J       Date:  2011-03-29       Impact factor: 2.979

3.  Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children.

Authors:  Amanda Ross; Nicolas Maire; Elisa Sicuri; Thomas Smith; Lesong Conteh
Journal:  PLoS One       Date:  2011-04-07       Impact factor: 3.240

Review 4.  It Is Time to Strengthen the Malaria Control Policy of the Democratic Republic of Congo and Include Schools and School-Age Children in Malaria Control Measures.

Authors:  Sabin S Nundu; Shirley V Simpson; Hiroaki Arima; Jean-Jacques Muyembe; Toshihiro Mita; Steve Ahuka; Taro Yamamoto
Journal:  Pathogens       Date:  2022-06-26

Review 5.  Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review.

Authors:  Junior R Matangila; Patrick Mitashi; Raquel A Inocêncio da Luz; Pascal T Lutumba; Jean-Pierre Van Geertruyden
Journal:  Malar J       Date:  2015-11-14       Impact factor: 2.979

6.  Intermittent preventive treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine regimens in schoolchildren of the Democratic Republic of Congo: a study protocol for a randomized controlled trial.

Authors:  Joachim Yorokpa Doua; Junior Matangila; Pascal Lutumba; Jean-Pierre Van Geertruyden
Journal:  Trials       Date:  2013-09-24       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.